Bystryn JC - Search Results

1

Preparation and characterization of a polyvalent human melanoma antigen vaccine.

Bystryn JC, Jacobsen S, Harris M, Roses D, Speyer J, Levin M. Bystryn JC, et al. J Biol Response Mod. 1986 Jun;5(3):211-24. J Biol Response Mod. 1986. PMID: 3723138

2

Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine.

Oratz R, Cockerell C, Speyer JL, Harris M, Roses D, Bystryn JC. Oratz R, et al. Among authors: bystryn jc. J Biol Response Mod. 1989 Aug;8(4):355-8. J Biol Response Mod. 1989. PMID: 2754436

3

Immunogenicity of a polyvalent melanoma antigen vaccine in humans.

Bystryn JC, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JL. Bystryn JC, et al. Cancer. 1988 Mar 15;61(6):1065-70. doi: 10.1002/1097-0142(19880315)61:6<1065::aid-cncr2820610602>3.0.co;2-l. Cancer. 1988. PMID: 3342366

4

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma.

Bystryn JC, Oratz R, Roses D, Harris M, Henn M, Lew R. Bystryn JC, et al. Cancer. 1992 Mar 1;69(5):1157-64. doi: 10.1002/cncr.2820690516. Cancer. 1992. PMID: 1739915

5

Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.

Oratz R, Dugan M, Roses DF, Harris MN, Speyer JL, Hochster H, Weissman J, Henn M, Bystryn JC. Oratz R, et al. Among authors: bystryn jc. Cancer Res. 1991 Jul 15;51(14):3643-7. Cancer Res. 1991. PMID: 2065322 Clinical Trial.

6

Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine.

Miller K, Abeles G, Oratz R, Zeleniuch-Jacquotte A, Cui J, Roses DF, Harris MN, Bystryn JC. Miller K, et al. Among authors: bystryn jc. Cancer. 1995 Jan 15;75(2):495-502. doi: 10.1002/1097-0142(19950115)75:2<495::aid-cncr2820750212>3.0.co;2-s. Cancer. 1995. PMID: 7812920

7

Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.

Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF. Bystryn JC, et al. Clin Cancer Res. 2001 Jul;7(7):1882-7. Clin Cancer Res. 2001. PMID: 11448900 Clinical Trial.

8

Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.

Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, Bystryn JC. Reynolds SR, et al. Among authors: bystryn jc. Clin Cancer Res. 2003 Feb;9(2):657-62. Clin Cancer Res. 2003. PMID: 12576432

9

Use of vaccines in treatment of malignant melanoma.

Bystryn JC, Shapiro RL, Harris M, Roses DF, Oratz R. Bystryn JC, et al. Clin Dermatol. 1996 Jul-Aug;14(4):337-41. doi: 10.1016/0738-081x(96)00063-6. Clin Dermatol. 1996. PMID: 8862911 Free article. Review. No abstract available.

10

Decrease in circulating tumor cells as an early marker of therapy effectiveness.

Bystryn JC, Albrecht J, Reynolds SR, Rivas MC, Oratz R, Shapiro RL, Roses DF, Harris MN, Conrad A. Bystryn JC, et al. Recent Results Cancer Res. 2001;158:204-7. doi: 10.1007/978-3-642-59537-0_21. Recent Results Cancer Res. 2001. PMID: 11092048

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

217 results

Search Page

Filters